Erratum: Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment (Journal of Rheumatology (2019) 46 (7-18) DOI: 10.3899/jrheum.171361);Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment

Journal of Rheumatology

Volumn 46, Issue 1, 2019, Pages 7-18

  Smolen, Josef S ^a   Genovese, Mark C ^b   Takeuchi, Tsutomu ^c   Hyslop, David L ^d   Macias, William L ^d   Rooney, Terence ^d   Chen, Lei ^d   Dickson, Christina L ^d   Riddle Camp, Jennifer ^d   Cardillo, Tracy E ^d   Ishii, Taeko ^d   Winthrop, Kevin L ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c KEIO UNIVERSITY   (Japan)

^d ELI LILLY AND COMPANY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Baricitinib; Clinical Trials; Janus kinase inhibitor; Rheumatoid arthritis; Safety

Indexed keywords

BARICITINIB; PLACEBO; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; METHOTREXATE; SULFONAMIDE;

ADULT; ALL CAUSE MORTALITY; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BLADDER DISEASE; BREAST DISEASE; BRONCHITIS; CARDIOVASCULAR DISEASE; CELLULITIS; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; FEMALE; GASTROENTERITIS; HEADACHE; HEART DISEASE; HEPATOBILIARY DISEASE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOPATHOLOGY; INCIDENCE; INFLUENZA; INNER EAR DISEASE; KIDNEY DISEASE; LONG TERM EXPOSURE; LUNG EMBOLISM; LYMPHATIC SYSTEM DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SKIN DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE TIME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85057868459     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.171361.C1     Document Type: Erratum

References (50)

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38.
2. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46.
3. Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101-36.
4. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298-307.
5. Iwata S, Tanaka Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2016;12:1047-57.
6. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
7. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652-62.
8. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243-52.
9. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.
10. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506-17.
11. Payne C, Zhang X, Shahri N, Williams W, Cannady E. Evaluation of potential drug-drug interactions with baricitinib [abstract]. J Managed Care Spect Pharm 2014;20:S51-2.
12. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333-40.
13. Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. J Rheumatol 2016;43:504-11.
14. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S100-8.
15. Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf 2004;13:295-8.
16. Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol 1994;37:401-4.
17. Singh JA, Saag KA, Bridges SL Jr, Akl AE, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
18. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 2012;64:640-7.
19. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
20. National Cancer Institute. DCTD, Division of Cancer Treatment and Diagnosis. CTEP, Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0 (CTCAE). [Internet. Accessed July 20, 2018.] Available from: ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
21. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, et al, editors. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. [All Cancer Sites (Invasive) Age-Specific SEER Incidence Rates, 2010-2014, Table 2.7]. Bethesda, Maryland. Based on November 2016 SEER data submission, posted to the SEER Web site April 2017. [Internet. Accessed July 20, 2018.] Available from: seer.cancer.gov/csr/1975_2014
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry on drug-induced liver injury: premarketing clinical evaluation. July 2009. [Internet. Accessed July 20, 2018.] Available from: www.fda.gov/downloads/guidances/UCM174090.pdf
23. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47.
24. Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011;10:289-300.
25. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
26. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies. J Rheumatol 2014;41:837-52.
27. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253-62.
28. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
29. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
30. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53-61.
31. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015;74:1311-6.
32. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54.
33. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
34. Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015;74:2107-16.
35. Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1133-8.
36. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
37. Yamaoka K. Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: A focus on herpes zoster. Drug Saf 2016; 39:823-40.
38. Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2924-37.
39. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017;13:234-43.
40. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909-16.
41. Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376-86.
42. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4.
43. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
44. Curtis JR, Lee EB, Martin G, Mariette X, Terry KK, Chen Y, et al. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme. Clin Exp Rheumatol 2017;35:614-22.
45. Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 2016;75:831-41.
46. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res 2013;65:1600-7.
47. Ogdie A, Kay McGill N, Shin DB, Takeshita J, Jon Love T, Noe MH, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J 2017 Apr 20 (E-pub ahead of print).
48. Romero-Diaz J, Garcia-Sosa I, Sanchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009;36:68-75.
49. Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 2016;68:2612-7.
50. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). May 2001. Guidance for industry: E 10 choice of control group and related issues in clinical trials. [Internet. Accessed July 20, 2018.] Available from: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073139.pdf